Innoviva, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Pavel Raifeld
- Full Time Employees
- 159
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1350 Old Bayshore Highway Burlingame CA United States of America 94010
- IPO Date
- Oct 5, 2004
- CIK
- 0001080014
- Website
- inva.com
- Similar Companies
- Business
- Innoviva, Inc. (INVA) is a diversified holding company focused on healthcare royalty management and the development and commercialization of therapies in critical care and infectious diseases. Founded in 2014 following a spin-off from Theravance, Inc., the company is headquartered in Burlingame, California, and operates primarily in the United States with international royalty streams. Its core royalty portfolio, derived from long-term agreements with Glaxo Group Limited (GSK) under the Long-Acting Beta2 Agonist (LABA) Collaboration, includes royalties on respiratory products such as RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) for chronic obstructive pulmonary disease (COPD) and asthma, ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and TRELEGY ELLIPTA; the company also markets proprietary critical care and anti-infective products through Innoviva Specialty Therapeutics, including GIAPREZA (angiotensin II) for increasing blood pressure in adults with septic or distributive shock, XERAVA (eravacycline) for complicated intra-abdominal infections, XACDURO (sulbactam-durlobactam) for hospital-acquired and ventilator-associated bacterial pneumonias caused by Acinetobacter, and ZEVTERA (ceftobiprole medocaril sodium) for Staphylococcus aureus bloodstream infections, acute bacterial skin infections, and community-acquired bacterial pneumonia. Innoviva's late-stage pipeline features zoliflodacin, a Phase III investigational oral treatment for uncomplicated gonorrhea. Recent developments include a December 2024 exclusive U.S. licensing and distribution agreement with Basilea Pharmaceutica for ZEVTERA, involving a $4 million upfront payment, tiered royalties, and planned commercialization in mid-2025; a March 2025 $10 million secured credit agreement with Armata Pharmaceuticals to advance phage therapeutics for antibiotic-resistant infections; and an ongoing strategic partnership with Sarissa Capital Management LP.
Company News
Innoviva to Participate in Upcoming Investor Conferences
Hsbc Holdings PLC Buys Shares of 49,428 Innoviva, Inc. $INVA
Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
Supernus Pharmaceuticals Q2 Earnings Call Highlights
Dimensional Fund Advisors LP Acquires 76,026 Shares of Innoviva, Inc. $INVA
Nortiva Bio Launches to Develop Long-Acting Oral Medicines
Nortiva Bio Launches to Develop Long-Acting Oral Medicines
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets
Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Innoviva to Participate in Upcoming Investor Conferences
Innoviva to Participate in Upcoming Investor Conferences
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
Innoviva (INVA) Tops Q1 Earnings Estimates
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
Merck (MRK) Reports Q1 Loss, Tops Revenue Estimates
Innoviva, Inc. (NASDAQ:INVA) Given Consensus Recommendation of “Moderate Buy” by Brokerages
3 Bargain-Cheap Small Caps Worth a Second Look